

# Stratification of hypertensive COVID-19 patients by quantitative NMR spectroscopy of serum metabolites, lipoproteins and inflammation markers

Jasmin Kazenwadel<sup>1</sup>, Georgy Berezhnoy<sup>1</sup>, Claire Cannet<sup>2</sup>, Hartmut Schäfer<sup>2</sup>, Tobias Geisler<sup>3</sup>, Anne-Katrin Rohlfing<sup>3</sup>, Meinrad Gawaz<sup>3</sup>, Uta Merle<sup>4†</sup>, Christoph Trautwein<sup>1\*†</sup>

<sup>1</sup> Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany

<sup>2</sup> Bruker BioSpin GmbH, Applied Industrial and Clinical Division, Ettlingen, Germany

<sup>3</sup> Department of Internal Medicine III, Cardiology and Angiology, University Hospital Tübingen, Tübingen, Germany

<sup>4</sup> Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany

\* Author to whom correspondence should be addressed: [Christoph.Trautwein@med.uni-tuebingen.de](mailto:Christoph.Trautwein@med.uni-tuebingen.de)

† These authors contributed equally to this work.

## Abstract

**Background:** The exact pathophysiology of humans suffering from the multifaceted SARS-CoV-2 infection is not yet conclusively understood and risk stratification is needed. Novel diagnostic approaches like the nuclear magnetic resonance spectroscopy (NMR) based quantification of metabolites, lipoproteins, and inflammation markers has helped to identify typical alterations in the blood serum of COVID-19 patients. However, important confounders such as age, sex, and comorbidities, which strongly influence the metabolome, were often not considered. Therefore, the aim of this NMR study was to consider gender, as well as arterial hypertension (AHT) which affects more than 1.2 billion people worldwide, when investigating COVID-19-positive serum samples in a large age-matched cohort. As AHT is a risk factor for severe COVID-19 disease, this study focuses on comparing metabolomic characteristics of COVID-19 patients with and without AHT.

**Methods and Findings:** NMR serum data from 329 COVID-19 patients were compared with 305 individuals from a healthy age and sex-matched control cohort. 134 of the 329 COVID-19 patients were affected by AHT. These were analyzed together with NMR data from 58 hypertensives without COVID-19. In addition to metabolite, lipoprotein, and glycoprotein data from NMR, common laboratory parameters were considered. Statistical comparison of the COVID-19 cohort with the control cohort reproduced results of previous studies. However, several differences emerged when AHT was considered. Especially, the previously described triglyceride-rich lipoprotein profile was no longer observed in COVID-19 patients, nor was an increase in ketone bodies. Typical metabolic changes that were apparent in COVID-19 patients in both sexes and with AHT were an increase in C-reactive protein (CRP) and the ratio of total glycoprotein (Glyc) to supramolecular phospholipids composite (SPC) which is an inflammatory NMR parameter. Further alterations were a decrease in glutamine, leucine, isoleucine, and lysine, citric acid, HDL-4 particles, and total cholesterol. Typical metabolic cardiovascular risk markers could be detected in hypertensive COVID-19 patients, as well as higher inflammatory NMR parameters than in normotensive COVID-19 patients.

**Conclusion:** We could show that a more precise picture of COVID-19 blood serum parameters emerge when AHT is considered which accordingly should be included in future studies and would help for a refined patient stratification.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 48 **Abbreviations**

<b>Name</b>	<b>Extended name</b>
<b>ACEI</b>	Angiotensin- converting- enzyme inhibitor
<b>AHT</b>	Arterial hypertension
<b>AT1RB</b>	Angiotensin-1 receptor blockers
<b>AUC</b>	Area under the curve
<b>BB</b>	Beta blockers
<b>BCAA</b>	Branched chained amino acids (leucine, isoleucine, valine)
<b>BP</b>	Blood pressure
<b>BUN</b>	Blood urea nitrogen
<b>CCB</b>	Calcium channel blockers
<b>Creatinine.lab</b>	Creatinine (laboratory report)
<b>CRP</b>	C- reactive protein
<b>FC</b>	Fold change
<b>FDR</b>	False Discovery rate
<b>GFR</b>	Glomerular filtration rate
<b>GGT</b>	Gamma-glutamyl transferase
<b>Glyc</b>	Glycoproteins
<b>GOT</b>	Glutamate- oxalacetate- transferase
<b>HC</b>	Healthy cohort
<b>Leuk</b>	Leucozytes
<b>LDH</b>	Lactat dehydrogenase
<b>NMR</b>	Nuclear magnetic resonance
<b>SPC</b>	Supramolecular phospholipid composite
<b>T2DM</b>	Diabetes mellitus Type 2
<b>TMAO</b>	Trimethylamine-N-oxide
<b>PACS</b>	Post-acute-covid- syndrom
<b>PCA</b>	Principal component analysis
<b>RAASI</b>	Renin-angiotensin-aldosterone- system inhibitors

49

## 50 **Introduction**

51 To date, the SARS- CoV- 2 virus, which emerged in Wuhan, China in December 2019, has infected  
52 more than 612 million people worldwide and caused 6.5 million deaths from December 2019 to  
53 September 2022 (WHO). COVID-19 infection can manifest in a wide range of symptoms with varying  
54 disease severity. Patients often report mild flu-like symptoms or asymptomatic courses. In some  
55 cases, however, intensive medical treatment may be necessary or the infection may be fatal.  
56 Furthermore, various complications can arise during the course of the disease, which can affect  
57 multiple organ systems. These include sepsis, acute respiratory distress syndrome (ARDS) (1), and  
58 thromboembolic events such as pulmonary emboli (2) or myocardial infarction (3). Since the  
59 beginning of the pandemic, there have been extensive efforts to identify causes and risk factors for

60 severe COVID-19 progression. Several studies have demonstrated that higher age, male gender, and  
61 pre-existing conditions such as arterial hypertension (AHT) or diabetes mellitus (DM) may be risk  
62 factors for a more severe COVID-19 course and hospitalization. (4, 5).

63 One way to better understand COVID-19 disease is the use of novel quantitative omics approaches  
64 such as nuclear magnetic resonance (NMR) spectroscopy. With this method, a variety of metabolites  
65 and lipoproteins can be rapidly quantified in serum from numerous samples. Thus, a metabolic  
66 fingerprint of a disease can be identified, which can help to better understand pathogenesis,  
67 therapeutic effects, and to identify biomarkers for a more comprehensive diagnosis (6, 7). For COVID-  
68 19, several studies have investigated the metabolome and lipoproteome of patient sera both in the  
69 acute stage of infection and in the so-called post-acute COVID syndrome. In these studies, it is  
70 apparent that there are diverse changes in metabolites during COVID-19 infection. These include a  
71 decrease in various amino acids such as histidine, glutamine, lysine, methionine and tyrosine,  
72 whereas the amino acid phenylalanine showed increased levels in the studies in COVID-19 patients,  
73 and furthermore a general increase in ketone bodies was observed (8-10). COVID- 19 patients also  
74 showed signs of dyslipidemia with increased levels of very low density lipoprotein (VLDL) particles,  
75 triglycerides in total plasma and in lipoprotein subgroups, and a decrease in high density (HDL) and  
76 low density lipoprotein (LDL) major and subgroups, which include phospholipids, cholesterol, and  
77 apolipoproteins A1 and A2 (8, 11-14). Also, the ABA1 ratio (apolipoprotein B100 divided by  
78 apolipoprotein A1) which is considered a cardiovascular risk marker (15), was increased in several  
79 COVID-19 cohorts (12, 13). In addition to the quantification of metabolites and lipoproteins in COVID-  
80 19 patients, it was possible to make statements about the outcome of patients (9). Accordingly, in  
81 hospitalized patients with positive outcome, i.e., in Baranovicova et al. survivors without respiratory  
82 deterioration or mechanical ventilation, normalization of energy metabolism occurred more rapidly,  
83 as well as an increase in glutamine, than in patients with negative outcome (deterioration of  
84 respiratory situation with need for respiratory support or death). Furthermore, NMR technology has  
85 identified markers that may be indicative of a severe COVID-19 progression (10, 16-18). As such,

86 above all, increased ketone bodies (16), phenylalanine (16, 17) and pronounced dyslipidemia with  
87 increased ABA1 ratio, decreased HDL cholesterol (16) and decreased apolipoprotein A1 (18) had  
88 been mentioned. These markers could help to predict response to therapy (16, 19). This was  
89 investigated in these two studies with the IL-6 inhibitor tocilizumab, where under and after therapy,  
90 respectively, an approximation of the metabolic/lipoproteomic parameters of severe COVID-19 cases  
91 to the levels of milder cases was observed. Regarding the post-acute COVID syndrome (PACS), which  
92 can also present with a wide range of symptoms (20) and precise disease mechanisms are still  
93 unclear, NMR spectroscopy has shown that PACS is associated with delayed metabolic  
94 phenoreversion and that the metabolome and lipoproteome still differ from healthy controls one to  
95 three months after acute infection (21, 22).

96 In addition to the metabolites and lipoprotein fractions discussed so far, N- acetylated- glycoproteins  
97 can be quantified by NMR as well. These include the GlycA signal, which is caused by various acute  
98 phase proteins such as haptoglobin,  $\alpha$ 1-acid glycoprotein,  $\alpha$ 1- antitrypsin,  $\alpha$ 1- antichymotrypsin and  
99 transferrin. (23). GlycA is combined with GlycB, which represents N-acetylneuraminic acid (24), to  
100 form the Glyc signal and thus maps inflammatory processes (25). Furthermore, Glyc is associated  
101 with increased cardiovascular risk (26, 27). Elevated Glyc levels were also found in COVID-19 (14).  
102 Another recent NMR parameter is the supramolecular phospholipids composite peak (SPC), which  
103 correlates mainly with apolipoproteins and HDL subfractions and is thus decreased in COVID-19  
104 sufferers (28).

105 As mentioned earlier, cardiovascular disease and diabetes mellitus are among the risk factors for  
106 more severe COVID-19 progression (4). These diseases also exhibit diverse alterations in the  
107 metabolome and lipoproteome. E.g. in patients with essential arterial hypertension, altered amino  
108 acid metabolism has been found, with decreased alanine and methionine levels, and increased  
109 arginine levels (29). Lactate and pyruvate were also elevated in hypertensives in one study (30).  
110 Furthermore, hypertensive patients show increased levels of cholesterol and triglycerides, as well as  
111 increased VLDL and LDL particles with reduced HDL and thus also an increased ABA1 ratio. (31).

112 Elevated serum phenylalanine levels and monounsaturated fatty acids were markers of increased  
113 cardiovascular risk in another study (32). Changes in amino acid metabolism are also found in type 2  
114 diabetes mellitus (T2DM), indicating impaired energy metabolism (33). In particular, impaired  
115 branched chained amino acid metabolism was conspicuous in this study in diabetic patients with late  
116 complications.

## 117 **Aim of this study**

118 Cardiovascular disease has both a high prevalence and an impact on metabolites and lipoproteins  
119 concentrations in blood serum. Previous studies have taken this mostly not into account when  
120 investigating the metabolic phenotype of COVID-19 acute disease. Therefore, in this study, NMR data  
121 and laboratory parameters from 58 uninfected hypertensive individuals were compared with 216  
122 samples of COVID-19 affected individuals also suffering from hypertension, and the influence of AHT  
123 on the previous findings on metabolic characteristics of COVID-19 was investigated. In our analyses,  
124 we demonstrated that the stratification for AHT resulted in a well-refined picture of the NMR based  
125 metabolic phenotype of COVID-19. Furthermore, 509 samples of COVID-19 affected individuals with  
126 and without hypertension were compared to derive conclusions about risks that could drive a severe  
127 disease progression. It was found that hypertensive patients with COVID-19 showed metabolic  
128 cardiovascular risk factors and increased inflammatory parameters.

## 129 **Material and Methods**

### 130 **Patient cohort & sample collection**

131 The COVID-19 study population (September 7th 2020 to May 17th 2021) consisted of patients  
132 monitored with the “Coronataxi digital early warning” (CDEW) system deployed in Rhein-Neckar  
133 County and Heidelberg, Germany - an outpatient care system consisting of remote digital monitoring  
134 via a mobile application (with symptom questionnaire and daily pulse oximetry), a medical doctor  
135 dashboard and medical care delivery to COVID-19 patients in home quarantine when indicated (34).

136 Visits in home quarantine were initiated when, based on the data obtained from the initial survey  
137 and all available self-reported data (e.g. self-reported dyspnea), a medical doctor at the university  
138 hospital decided whether a visit in home quarantine by a nurse was indicated and scheduled the visit  
139 for the following day.

140 This was a prospective non-interventional study conducted at the University of Heidelberg. Patients  
141 were eligible if they for were diagnosed with SARS-CoV-2 infection and if they had consented to  
142 study participation. Written informed consent according to the Declaration of Helsinki was obtained  
143 for all patients and the local Ethics committee had approved data collection and analysis (reference  
144 number: S-324/2020).

145 Blood sample collection took place during home visits by nurses (the cohort and study therefore was  
146 called "Coronataxi"), which were carried out on medical indication e.g. worsening of symptoms.

147 Therefore, the blood samples were not taken a fastened state and there are various numbers of  
148 samples per study participant from zero to three. Also, the time intervals between blood collections  
149 varied. From a total of 459 participants in the Coronataxi study, a total of 543 samples from 348  
150 COVID-19 patients was received and investigated by NMR. In interest to get the full statistical power,  
151 we took chance of using the NMR data of all samples, even there were several specimens of the  
152 same patient. This is a common approach in metabolomics studies. Blood was collected in Li-heparin  
153 or EDTA- containing tubes. The specimens were then transported in isolated polystyrene boxes and  
154 centrifuged for serum preparation in the afternoon in the laboratory of Heidelberg University  
155 Hospital, Germany. A frozen aliquot of the supernatant of these samples was transported to  
156 Tübingen, Germany on dry ice and stored at -80 degrees Celsius until further processing and NMR  
157 analysis

158 Besides common laboratory parameters (e.g. creatinine, C- reactive protein, white blood cell count  
159 and other) extensive metadata were provided by the University hospital Heidelberg, Heidelberg,

160 Germany e.g. information about anthropometrics, age, medication and pre- existing diseases. The  
161 metadata is listed in Table 1 and in the supplementary data S1.

162 The cohort of the 58 arterial hypertension patients were provided by the interdisciplinary  
163 biomaterial- and databank of Würzburg University Hospital, Germany and were age and sex matched  
164 with the Heidelberger COVID-19 cohort. They were stored at -80 degrees Celsius, until further  
165 processing. The metadata belonging to the serum samples was provided by the institute for clinical  
166 epidemiology and biometry Würzburg, Germany. Study enrollment of participants and collection of  
167 samples took place between July 2019 and February 2022. The pre-disease AHT was recorded as part  
168 of the patient's medical history. Further metadata contained information about age, sex, medication,  
169 diabetes mellitus as co- disease and common laboratory parameters, including renal values  
170 (creatinine, blood urea nitrogen, GFR), small blood count, inflammatory values (e.g., CRP), and  
171 isolated liver values. The relevant metadata for this work is listed in Table 2. An overview about the  
172 antihypertensive treatment is given in Table 3. For the patient recruitment, which took place in  
173 Tübingen, Germany, there is an ethics vote with the number 141/2018BO2, dated May 4, 2022. Since  
174 the data were kept in Würzburg, Germany, there is a second ethics vote with the number 52/18.  
175 For improved statistical analysis, further NMR data (metabolites and lipoproteins) of an age and sex  
176 matched healthy control cohort (HC) of 305 subjects were provided by Bruker BioSpin GmbH  
177 (Ettlingen, Germany). These data did not contain any clinical laboratory parameters.

## 178 **Sample preparation and NMR measurement**

179 The raw NMR spectra were acquired using Bruker's body fluids NMR methods package  
180 [[https://www.bruker.com/de/products-and-solutions/mr/nmr-clinical-research-solutions/b-i-](https://www.bruker.com/de/products-and-solutions/mr/nmr-clinical-research-solutions/b-i-methods.html)  
181 [methods.html](https://www.bruker.com/de/products-and-solutions/mr/nmr-clinical-research-solutions/b-i-methods.html)]. The sample preparation was performed following standard operating procedures  
182 (SOPs) to perform reproducible results. Briefly, blood serum samples were thawed to room  
183 temperature. Then 400 µl of commercially available plasma/serum buffer (Bruker BioSpin GmbH,  
184 Ettlingen, Germany) were pipetted into a 1,5 ml sterile Eppendorf tube. Next, an aliquot of 400 µl

185 serum was added to the buffer. After gently shaken, an aliquot of 600  $\mu$ l of the mixture was  
186 transferred into a 5 mm Bruker SampleJet NMR tube. Since only 350  $\mu$ l was available for the cohort  
187 with the 58 hypertensive patients, 320  $\mu$ l serum aliquot was added to 320  $\mu$ l Bruker Plasma buffer  
188 (resulting in the same 1:1 mixing ratio) and an aliquot of 600  $\mu$ l was used for measurement.

189 NMR spectroscopy was performed with a Bruker BioSpin IVDr Avance III HD 600 MHz system. It uses  
190 a temperature-controlled autosampler SampleJet™ for gentle handling during the measurements. 1D  
191 <sup>1</sup>H-NMR spectra of the NOESY experiment (Nuclear Overhauser Spectroscopy) at a temperature of  
192 310 K were acquired. NOESYs were analyzed using Bruker's software TopSpin (Version 3.6.2) and  
193 automatically processed. For the highest standardization and amount of reproducibility the following  
194 NMR-based commercial IVDr SOPs (standard operation procedures) were used to collect the data  
195 sets for quality control, metabolites, lipoproteins, and inflammatory markers: B.I.BioBankQC™ in  
196 Plasma/Serum (Quality Control for Biobank Blood Samples), B.I.Quant-PS™ (quantification of up to  
197 41 metabolites in serum in mmol/L), B.I.LISA™ (Lipoprotein analysis for 112 lipoprotein variables in  
198 serum), and B.I. PACS™ (quantification of two metabolites, nine lipoprotein variables, SPC and  
199 inflammatory markers e.g., GlycA/GlycB and Glyc/SPC ratio which provide information related to  
200 various complications in the context of post-acute COVID-19 syndrome).

201 Lipoprotein concentrations provided by the B.I. LISA™ package are divided in various subfractions  
202 broken down by triglycerides (TG), cholesterol (CH), apolipoproteins A1/ -A2, apolipoprotein B100  
203 bearing particles (AB), and total particle numbers (PN). These subfractions exist in the individual  
204 lipoprotein classes, very-low-density (VLDL), intermediate density (IDL), low-density (LDL), and high-  
205 density lipoproteins (HDL). Additionally, the above mentioned subfractions (TG, CH, A1, A2, AB, PN)  
206 are also available in total plasma concentrations (TP). Phospholipid (PL) and free cholesterol (FC)  
207 fractions are also provided within the lipoprotein panel. Furthermore, the lipoproteins are  
208 subdivided according to size and thus increasing density. VLDL can be subdivided by NMR into five  
209 sizes, LDL into six, and HDL into four whereas an increasing number is associated with smaller size or  
210 higher density.



211 Glycoproteins (Glyc A, Glyc B, Glyc) and the supramolecular phospholipid composite (SPC) data from  
212 the B.I. PACS™ module were available for the COVID-19 cohort and the AHT control cohort, but not  
213 for the HC from Bruker.

#### 214 **Quality control, Statistics and Data illustration**

215 To increase the quality of the NMR data set, the above-mentioned quality control reports of the  
216 individual samples were checked and a total of 26 samples were sorted out based on these, mainly  
217 due to a linewidth of > 2.3 Hz. This resulted in a total 509 samples from 329 COVID-19 patients and  
218 58 samples from 58 hypertension patients were investigated.

219 The software package MetaboAnalyst 5.0 was used for statistical analysis of the obtained  
220 quantitative NMR reports. To change the data as little as possible, no normalization or scaling has  
221 been applied as NMR measurements are highly reproducible and results are based on absolute  
222 quantification. Only log transformation was performed to correct for heteroskedasticity. Features  
223 with > 50% missing values have been removed. The other missing values were estimated with k-  
224 nearest neighbors (KNN) based on similar features. As univariate test method, volcano plots, which  
225 corresponds to a combination of unpaired t-test and fold change (FC) analysis, were used to  
226 determine significant alterations of metabolites and lipoproteins. Thereby a p-value threshold of <  
227 0.05 and FC threshold of 1.2 were set. For false discovery rate (FDR) control, Benjamini- Hochberg  
228 procedure was used. For multivariate statistics, unsupervised principal component analysis (PCA) was  
229 performed to get an overview of the clustering and to identify outliers. Features such as the 2D  
230 scores plots, loadings plots, and biplots were used for this purpose. For Table 4, the Biomarker  
231 analysis was used to elaborate the most prominent alterations of the respective comparisons. From  
232 all significant metabolites, lipoproteins, and laboratory parameters in the volcano plot analyses,  
233 those 15 with the highest area under the curve (AUC) were chosen and are listed in Table 4.

234 Plots of multivariate statistics were used from MetaboAnalyst 5.0. Further, violin plots and volcano  
235 plots included in this article were created with GraphPad Prism 9. The consort diagram (Fig 1) was  
236 created with Microsoft PowerPoint 2019.

## 237 Results

### 238 Cohort composition

239 The main characteristics of the Coronataxi cohort are shown in Table 1. As this cohort was divided in  
240 a normotensive and hypertensive COVID-19 patient group, some characteristics for these are listed  
241 separately in Table 2, along with the AHT control cohort.

242 *Table 1. Characteristics of the COVID-19 cohort in total and sample collection*

Characteristics	Total	Female	Male
Gender, no. (%)	329	174 (52.9)	155 (47.1)
Age, median (IQR)	54 (44- 64)	52 (41- 63)	58 (48- 65)
BMI, median (IQR)	27.9 (24.4- 32.2)	26.7 (22.6- 32)	29 (25.9- 32.3)
Hospital treatment, no. (%)	71 (21.6)	25 (7.6)	46 (14)
Death, no. (%)	5 (1.5)	3 (0.9)	2 (0.6)
Arterial hypertension (%)	134 (40.7)	63 (19.1)	71 (21.6)
<b>Medication (antihypertensives)</b>			
Beta-blockers (%)	61 (18.5)	31 (9.4)	30 (9.1)
Calcium channel blockers (%)	32 (9.7)	14 (4.3)	18 (5.5)
ACE- inhibitors (%)	43 (13.1)	17 (5.2)	26 (7.9)
AT1-R-blockers (%)	62 (18.8)	34 (10.3)	28 (8.5)
<b>Sample collection period</b>			
<b>Timepoint of collection</b>	<b>1</b>	<b>2</b>	<b>3</b>
Numbers of samples	319	137	53
Days after symptom onset, median (IQR)	7 (5-9)	10 (8-12)	11 (10-14)

243 *The characteristics of the COVID-19 cohort are separated by gender. Besides information about anthropometrics, age and*  
244 *hospitalization, arterial hypertension (AHT) as the most important pre-existing condition in this work and the*  
245 *antihypertensive treatment are listed. Other pre-existing diseases and medication are listed in the supplementary data S1*  
246 *Table. In some cases, multiple samples were collected per patient at a maximum of three time points. These are also given in*

247 *the table together with the mean time interval after symptom onset in days. IQR = interquartile range, BMI = body mass*  
 248 *index, ACE = Angiotensin- converting- enzyme, AT1-R = Angiotensin-1 receptor.*

249 **Table 2. Characteristics of the COVID-19 cohort, separated by regular blood pressure and AHT, and the AHT control cohort**

Characteristics	COVID- 19 regular BP	COVID- 19 AHT	AHT control cohort
Total	195	134	58
Gender, no. (%):			
Female	111 (56.9)	63 (47.0)	29 (50)
Male	84 (43.1)	71 (53.0)	29 (50)
Age, median (IQR)	49 (37- 60)	62 (53- 69)	57 (52- 61)
Hospital treatment, no. (%)	38 (19.5)	33 (24.6)	n.a.
CRP, median (IQR)	18.1 (8.7- 48.4)	21.3 (8.3- 57.8)	0.4 (0.1- 1.2)

250 *This table presents the relevant characteristics of the COVID- 19 cohort with regular BP and AHT, as well as the AHT control*  
 251 *cohort. Listed are the total patient numbers, gender, age, hospitalization, and the laboratory parameter C-reactive protein*  
 252 *(CRP). BP =blood pressure, AHT= arterial hypertension, IQR= interquartile range.*


253 **Table 3: Antihypertensive treatment of the AHT control cohort**

Antihypertensives	Total (%)	Female (%)	Male (%)
Beta-blockers (%)	42 (72.4)	21 (36.2)	21 (36.2)
Calcium channel blockers (%)	22 (37.9)	11 (19)	11 (19)
ACE- inhibitors (%)	24 (41.4)	14 (24.1)	10 (17.2)
AT1-R-blockers (%)	31 (53.4)	15 (25.9)	16 (27.6)

254 *This table shows the antihypertensive treatment with the four substance classes beta- blockers, calcium channel blockers,*  
 255 *ACE- inhibitors, AT1-R-blockers of the 58 patients in the AHT control cohort. ACE = Angiotensin- converting- enzyme, AT1-R =*  
 256 *Angiotensin-1 receptor.*

## 257 **Overview of the performed analyses and results**

258 In this work, NMR data from a healthy cohort (n= 305) were compared with NMR data of the COVID-  
 259 19 cohort in total (n= 509). Further, NMR data and laboratory parameters of COVID-19 affected  
 260 individuals with AHT (n=216) were compared with an AHT control cohort (n=58) to investigate the  
 261 impact of AHT on previous findings on metabolomic, lipoproteomic and inflammatory changes in  
 262 COVID-19 patients. These comparisons were additionally analyzed separately by gender. NMR data  
 263 and laboratory parameters were also analyzed from COVID- 19 patients with AHT (n=216) and  
 264 without (n= 293). The same was performed with samples of hospitalized COVID-19 patients, of which  
 265 33 individuals (sample n=56) suffered from AHT, while 38 patients (sample n=71) had a regular blood  
 266 pressure. Last, AHT patients with different antihypertensive treatment were compared. An overview  
 267 of all performed analyses is given in Fig 1.



268

269 **Fig 1. Consort diagram showing an overview of the cohorts**

270 *Presented are patient and sample numbers, which were used for the various analyses. HC= Healthy control, AHT= Arterial*

271 *hypertension, BP= Blood pressure, RAASI= Renin- angiotensin- aldosterone- system inhibitors.*

272

273 Table 4 is intended to provide an overview of the results of the individual univariate analyses.

274 Regardless of gender and prior AHT (columns 1, 4, 5), all COVID-19 patients showed an increase in

275 CRP, decreases in alanine, glutamine, lysine, pyruvate, and in the lipoprotein subgroups H4A1, H4CH,

276 and H4PL. Other common features not included in this presentation, due to a smaller AUC but still

277 showing significant changes in univariate statistics, were an increase in Glyc/SPC ratio, decreased

278 levels of citric acid, isoleucine, and leucine, as well as HDL- subgroups H4A2 and H4FC, total

279 cholesterol (TPCH), total apolipoproteins (TPA1, TPA2), and SPC. Interestingly, COVID-19 groups had

280 decreased leukocyte counts in contrast to the control group. There were differences of laboratory

281 parameters in COVID-19 affected depending on gender (column 2). This included higher levels of

282 creatinine, ferritin, gamma-glutamyl transferase (GGT) and blood urea nitrogen (BUN) in males. It

283 was also noticeable that men had higher inflammatory parameters in the form of Glyc/SPC. The

284 branched chained amino acids (BCAA) leucine and valine were increased in men. HDL subclasses

285 (HDL-1, -2, -3) were decreased. When COVID-19 + AHT affected women and men were compared  
 286 (column 3), there were some changes. In this subgroup, the BCAAs leucine and isoleucine were  
 287 increased in male patients, but the changes in lipoproteins now concerned LDL subgroups (mainly  
 288 the larger particles LDL-1 and -3), which showed lower levels in men than in women. When COVID-19  
 289 patients with normal blood pressure and AHT were compared (column 6), metabolic markers  
 290 associated with AHT were conspicuous in the hypertensive COVID-19 group. These included elevated  
 291 creatinine and BUN, a triglyceride-rich lipoprotein profile (IDTG, TPTG, VLTG, VLDL-1, -2), and the  
 292 intestinal metabolite trimethylamine-N-oxide (TMAO). The last mentioned was found to be elevated  
 293 only in the COVID-19 + AHT group. Hospitalized hypertensive COVID-19 patients (column 7), also  
 294 showed a triglyceride-rich lipoprotein profile compared with hospitalized normotensive COVID-19  
 295 patients. This was characterized by increased total and VLDL triglycerides (TPTG, VLTG), VLDL  
 296 particles (VLAB, VLDL-1, VLDL-2, VLDL-3), and, in contrast to the whole COVID-19 + AHT group, also  
 297 by an increase in HDL triglycerides (HDTG, H1TG, H2TG, H3TG). All group comparisons discussed  
 298 here, as well as additionally the comparison of the whole COVID-19 cohort with Bruker's HC and the  
 299 comparison of different antihypertensive treatment groups, will be discussed in detail in the next  
 300 chapters.

301 *Table 4. Overview of results of the individual group comparisons in the univariate statistics*

Parameter	1. COVID-19 + AHT vs. AHT	2. COVID-19: Male vs. Female	3. COVID-19 + AHT: Male vs. Female	4. Female: COVID-19 + AHT vs. AHT	5. Male: COVID-19 + AHT vs. AHT	6. COVID-19: AHT vs. Regular BP	7. Hospitalized COVID-19: AHT vs. Regular BP
Alanine	0.75 ↓****			0.73 ↓****	0.76 ↓****		
BUN		1.45 ↑****	1.57 ↑****			1.39 ↑****	
Citric acid	0.69 ↓****						
Creatine							0.46 ↓*
Creatinine		1.44 ↑****	1.43 ↑****			1.22 ↑****	1.35 ↑***
Creatinine.lab		1.47 ↑****	1.61 ↑****			1.24 ↑****	1.51 ↑***
CRP	4.41 ↑****			4.37 ↑****	4.27 ↑****		
Dimethylsulfone						0.52 ↓**	
Ferritin		3.11 ↑****					
Formic acid	0.48 ↓****				0.44 ↓****		
GGT		2.16 ↑****					
Glutamine	0.75 ↓****			0.78 ↓****	0.73 ↓****		

<b>Glyc/SPC</b>		1.26↑****			1.46↑***		
<b>H1A1</b>		0.73↓****					
<b>H1A2</b>		0.7↓****					
<b>H1CH</b>		0.74↓****					
<b>H1FC</b>		0.74↓****					
<b>H1PL</b>		0.73↓****					
<b>H1TG</b>							1.30↑*
<b>H2CH</b>		0.83↓****					
<b>H2TG</b>							1.26↑*
<b>H3FC</b>		0.8↓****					
<b>H3TG</b>							1.23↑*
<b>H4A1</b>	0.76↓****			0.77↓****	0.76↓****		
<b>H4A2</b>	0.74↓****				0.72↓****		
<b>H4CH</b>	0.71↓****			0.72↓****	0.71↓****		
<b>H4PL</b>	0.75↓****			0.76↓****	0.75↓****		
<b>HDA1</b>	0.83↓****			0.80↓****			
<b>HDA2</b>				0.83↓****			
<b>HDCH</b>				0.77↓****			
<b>HDTG</b>							1.23↑*
<b>IDTG</b>						1.43↑***	
<b>Isoleucine</b>			1.28↑***		0.66↓****		
<b>L1AB</b>			0.82↓****				
<b>L1CH</b>			0.8↓****				
<b>L1FC</b>			0.82↓***				
<b>L1PL</b>			0.81↓****				
<b>L1PN</b>			0.82↓****				
<b>L3AB</b>			0.78↓**				
<b>L3CH</b>			0.76↓***			0.79↓***	
<b>L3FC</b>			0.8↓**				
<b>L3PL</b>			0.78↓**			0.82↓***	
<b>L3PN</b>			0.79↓**				
<b>Leucine</b>		1.23↑****	1.35↑****				
<b>Leuk</b>	0.70↓****			0.67↓****	0.71↓***		
<b>Lysine</b>	0.64↓****			0.63↓****	0.64↓****		
<b>Methionine</b>					0.72↓****		
<b>Pyruvic acid</b>	0.34↓****			0.34↓****	0.34↓****		
<b>SPC</b>	0.76↓****			0.73↓****			
<b>TPA1</b>	0.82↓****			0.79↓****			
<b>TPA2</b>				0.80↓****			
<b>TPCH</b>					0.73↓****		
<b>TPTG</b>						1.22↑****	1.31↑*
<b>TMAO</b>						1.25↑*	
<b>V1CH</b>						1.31↑***	1.48↑*
<b>V1PL</b>						1.34↑***	1.43↑*
<b>V1TG</b>						1.34↑***	1.45↑*
<b>V2FC</b>						1.23↑**	1.43↑*
<b>V2TG</b>						1.23↑**	

V3FC							1.45 ↑*
Valine		1.2 ↑****					
VLAB							1.23 ↑*
VLTG					1.26 ↑***		1.34 ↑*

302 *This table gives an overview of the performed univariate analyses. These comparisons are further elaborated below and*  
303 *illustrated in volcano plots. The number indicated is the fold change. The arrow indicates whether a metabolite, lipoprotein*  
304 *or laboratory value was found to be decreased (blue) or increased (red) in the group marked in red, respectively. The p-value*  
305 *is indicated in form of asterisks ( $p < 0.05$  (\*),  $p < 0.01$  (\*\*),  $p < 0.001$  (\*\*\*),  $p < 0.0001$  (\*\*\*\*)). Since many metabolites were*  
306 *found to be significant in individual comparisons, the 15 that also showed the highest area under curve (AUC) in the*  
307 *Metaboanalyst 5.0 biomarker analysis were selected for this presentation. AHT= Arterial hypertension, BP= Blood pressure,*  
308 *BUN= Blood urea nitrogen, Creatinine.lab= Creatinine value from laboratory report, CRP= C-reactive protein, GGT= Gamma-*  
309 *glutamyl- transferase, Leuk= Leukocytes count, TMAO= Trimethylamine-N-oxide.*  
310


311 **Differences in the metabolomic phenotypic when comparing total COVID-19 patient cohort with**  
312 **sub-cohort of patients with hypertension**

313 For comparison with previously reported findings of NMR-based alterations of metabolites and  
314 lipoproteins, a volcano plot analysis was performed comparing the 305 samples of the HC with the  
315 entire Coronataxi COVID-19 cohort, i.e., 509 samples. All metabolic changes named below therefore  
316 apply to the comparison of the entire COVID-19 cohort with Bruker's HC and can be seen in the  
317 volcano plot in Fig 2A. In this plot, 60 metabolites and lipoproteins were decreased more than 1.2-  
318 fold, whereas 29 were increased. The metabolic changes largely coincided with the literature already  
319 cited in the introduction. A triglyceride-rich lipoprotein profile could be detected in the total COVID-  
320 19 cohort based on the elevated levels of total plasma triglyceride (TPTG), other triglyceride  
321 subgroups (IDTG, L1TG), all major VLDL groups (VLAB, VLPN, VLCH, VLFC, VLTG, and VLPL), and  
322 several VLDL subgroups (e.g. V1TG, V2CH, V3TG, V5FC, for example) in all sizes except VLDL-4. On the  
323 other hand, a reduction in total plasma apolipoproteins A1 and A2 and all major HDL- groups (HDA1,  
324 HDA2, HDCH, HDLC, HDPL), except HDTG, was observed in the COVID-19 cohort. All four sizes were  
325 present, with HDL-3 and -4 as the most significant subgroups, of which the apolipoprotein,  
326 phospholipid, and cholesterol subgroups were particularly represented. Furthermore, total plasma  
327 cholesterol (TPCH), several LDL major (LDCH, LDLC, LDPL), and subgroups, were shown to be  
328 decreased, this being mainly true for denser LDL subgroups (LDL-3, -4, -5, -6), as well as for the  
329 phospholipid and cholesterol subgroups (e.g., L4CH, L5PL, L6FC). For metabolites, we observed a  
330 decrease over 1.2-fold in several amino acids, including glutamine, lysine, histidine, leucine, and

331 isoleucine. Another reduced metabolite was citric acid. In contrast, ketone bodies (3-  
332 hydroxybutyrate, acetone), the amino acids phenylalanine and glutamic acid, and the metabolites  
333 succinic acid and dimethylglycine were increased in the COVID-19 cohort.

334 To see whether the results described above could be reproduced when stratifying for AHT, the  
335 COVID-19 cohort was divided into a hypertensive and a normotensive sub-cohort. The COVID-19  
336 cohort with AHT was compared with an AHT control group without COVID-19 using another volcano  
337 plot (Fig 2B). We could identify 60 metabolites, lipoproteins, and laboratory parameters which  
338 showed a decrease of more than 1.2 -fold in the COVID-19 + AHT cohort (as in the previous  
339 comparison), while 5 showed an increase (versus 29 increased features in the comparison COVID-19  
340 in total vs. HC). The main differences between those two comparisons were that we could not  
341 observe a triglyceride-rich lipoprotein profile in the COVID-19 + AHT cohort. Only the inflammatory  
342 parameters CRP and Glyc/SPC ratio, the amino acids glutamic acid and phenylalanine, and the citrate  
343 cycle metabolite succinic acid were elevated. The above-described increase in ketone bodies did not  
344 show up in the COVID-19 + AHT group. Furthermore, the significant reductions in HDL- fractions in  
345 COVID-19 + AHT patients were mainly concentrated on HDL-4 particles (H4A1, H4A2, H4CH, H4FC,  
346 H4PL), in contrast to the whole COVID-19 group. On the other hand, there were some features,  
347 which these two comparisons had in common, including decreases in amino acids lysine, glutamine,  
348 histidine, leucine, and isoleucine in the SARS-CoV-2 infected patients with and without AHT. In the  
349 COVID-19 + AHT cohort, additionally, the amino acids alanine, methionine, and tyrosine were  
350 decreased. Another common metabolite was citric acid, which showed decreased levels in COVID-19  
351 patients in total and in COVID-19 + AHT. As in the whole COVID-19 cohort, also in the hypertensive  
352 group, a reduction of TPCH and several LDL- major- (LDAB, LDCH, LDLC, LDPL) and subgroups could  
353 be observed. Again, mostly denser particles (LDL-4, -5, -6) and phospholipid and cholesterol fractions  
354 of LDL were present. Interestingly, a few major VLDL groups (VLFC, VLPL, VLTG) and isolated VLDL-1  
355 particles were also reduced in the COVID-19 + AHT cohort.





356

357 **Fig 2. Univariate comparisons by means of volcano plots showing the differences of the metabolome and lipoproteome in**  
 358 **COVID-19 + AHT patients compared to the COVID-19 cohort in total**

359 *FC > 1.2, p < 0.05, FDR < 0.01: The red features are significantly increased in the COVID-19 cohorts, respectively, while the*  
 360 *green ones are significantly decreased in COVID-19 affected. The features in red boxes showed up repeatedly in these and*  
 361 *following comparisons and were therefore typical altered in COVID-19 patients. (A) shows the comparison between the*  
 362 *COVID- 19 cohort in total with the HC. (B) shows the comparison between hypertensive COVID-19 patients and uninfected*  
 363 *hypertensive individuals. In (C) and (D) violin plots show the decreased respectively increased NMR parameters with the*  
 364 *highest significance for each comparison. The y-axis shows the normalized concentration. HC= Healthy control, AHT= Arterial*  
 365 *hypertension, Cov= COVID-19, CRP= C- reactive protein, Leuk= Leukocytes count.*  
 366


367

## 368 **Gender differences in COVID-19 patients with and without AHT**

369 In Fig 3A, a volcano plot was used to compare 155 (254 samples) male and 174 (255 samples) female  
370 COVID-19 patients from the cohort in total. Overall, 26 features were significantly increased in male  
371 COVID-19 patients, whereas 19 were decreased. Some gender-specific laboratory parameters were  
372 altered, such as creatinine, blood urea nitrogen (BUN), ferritin, and the liver values GGT and GOT,  
373 which showed higher values in men than in women. Furthermore, males with COVID-19 showed  
374 higher levels of Glyc/SPC ratio, BCAAs leucine, isoleucine, and valine, ketone bodies (acetones,  
375 acetoacetic acid, 3-hydroxybutyric acid), and various VLDL- subgroups, including triglyceride (VLTG,  
376 V1TG, V2TG), phospholipid (V1PL, V2PL, V3PL), and cholesterol (V1FC, V1CH, V2FC, V2CH, V3FC)  
377 fractions. In comparison, women showed higher values in HDL- subgroups. This was true for  
378 apolipoprotein (H1A1, H1A2), cholesterol (H1CH, H1FC, H2CH, H2FC, H3FC), phospholipid (H1PL), and  
379 triglyceride fractions (H1TG). HDL-4 did not stand out in the gender comparison. Furthermore, LDL  
380 particles were more abundant in female COVID-19 patients. Among them were the larger LDL-  
381 subgroups, like LDL- 1 (L1CH), LDL-2 (L2CH, L2PL), and LDL-3 (L3AB, L3CH, L3FC, L3PN, L3PL).

382 To examine the effect of AHT on metabolic sex differences in COVID-19 patients, the COVID-19 + AHT  
383 cohort was divided by sex. A volcano plot was performed with data from 124 samples from 71 men  
384 and 92 samples from 63 women with COVID-19 + AHT (Fig 3B). This comparison in the AHT subgroup  
385 revealed less significant differences than present in the total COVID-19 cohort. 10 features (vs. 26 in  
386 the male COVID-19 group in total) were significantly increased in males compared to females; 15  
387 features (vs. 19 in the male COVID-19 cohort in total) were decreased in male patients. The  
388 triglyceride-rich lipoprotein profile of men now was less pronounced, only isolated VLDL particles  
389 were elevated (V2FC, V2PL, V3PL). Ketone bodies no longer stood out as significant, nor did the  
390 Glyc/SPC ratio. Men showed higher levels of the BCAAs leucine and isoleucine, as well as citric acid,  
391 and dimethyl sulfone. Women continued to show higher values in the LDL fractions, but not in the  
392 HDL particles. Among them, LDL-1 (L1AB, L1CH, L1FC, L1PL, L1PN), LDL-2 (L2AB, L2PL), LDL-3 (L3AB,  
393 L3CH, L3FC, L3PL, L3PN), and LDL-4 (L4FC) were present.


394 The comparisons of COVID-19 + AHT with an AHT control group, as well as the gender comparisons,  
395 identified characteristics that are independent of gender and prior AHT disease and thus typical of  
396 COVID-19 infection in our cohort. These are shown as outlined in red in Fig 2 and 4. In the volcano  
397 plots, male and female hypertensive patients with and without COVID-19 were compared. There  
398 were 29 samples from 29 female hypertensive patients without COVID-19 and 92 samples from 63  
399 female hypertensive patients with COVID-19 and AHT. In male patients, 29 samples from 29  
400 hypertensive patients without and 124 samples from 71 patients with COVID-19 and AHT were also  
401 compared. In these analyses, metabolites and lipoproteins that were also apparent in the previous  
402 univariate statistics stood out. These included an increase in Glyc/SPC, glutamic acid and CRP, and a  
403 decrease in amino acids leucine, isoleucine, glutamine, and lysine, citric acid, and HDL-4 fractions  
404 (H4A1, H4A2, H4CH, H4FC, H4PL), total cholesterol (TPCH), and SPC.  
405



406

407 **Fig 3. Univariate comparisons by means of volcano plots showing gender differences of COVID-19 patients with and without AHT**

408  $FC > 1.2$ ,  $p < 0.05$ ,  $FDR < 0.01$ : The red features are significantly increased in men, respectively, while the green ones are significantly decreased in men, compared to women. (A) shows the comparison between the genders in the COVID-19 cohort in total. (B) shows the comparison between the genders in the COVID-19 + hypertension cohort. In (C) violin plots show the decreased respectively increased NMR parameters with the highest significance. In (D) the left violin plot shows L1CH, as the lipoprotein with the highest significance, which is decreased in males. The right violin plot shows leucine, as increased NMR parameter in males, with the second highest significance after creatinine. The y-axis shows the normalized concentration. AHT= Arterial hypertension, BUN= Blood urea nitrogen, Creatinine.lab= Creatinine from laboratory report, GGT= Gamma-glutamyl- transferase, GOT= Glutamate- oxalacetate- transferase, F= Female, M= Male.




417

418 **Fig 4. Univariate comparison of AHT cohorts with and without COVID-19, separated by gender, respectively**  
 419 *FC > 1.2, p < 0.05, FDR < 0.01: The red features are significantly increased in COVID-19 patients, while the green ones are*  
 420 *decreased. Plot (A) shows the comparison of AHT vs. AHT + COVID-19 for females, plot (B) shows this comparison for male*  
 421 *gender. Features in red boxes are common in both genders and in COVID-19 affected considering AHT. AHT= Arterial hyper-*  
 422 *tension, Creatinine.lab= Creatinine from laboratory report, CRP= C-reactive protein, 3-HBA= 3- Hydroxybutyric acid.*  
 423

424 **Hypertensive COVID-19 patients show NMR-based metabolomic and lipoproteomic characteristics**  
 425 **of an increased cardiovascular risk**

426 The aim of the next analysis was to compare hypertensive and normotensive COVID-19 patients to  
 427 investigate if there are metabolic alterations between those two groups which could indicate a  
 428 higher risk for a severe COVID-19 disease course. 216 samples from 134 hypertensive COVID-19  
 429 patients were compared with 293 samples from 195 normotensive COVID-19 patients. A volcano plot


430 (Fig 5) was performed, where 15 metabolites, lipoproteins, and laboratory parameters were  
431 increased more than 1.2- fold. Two lipoprotein subclasses (L3CH, L3PL) and one metabolite  
432 (dimethyl sulfone) were reduced. The highest significant alterations were seen in the elevated renal  
433 values in the hypertensive COVID-19 group. BUN and creatinine.lab corresponded to standard  
434 laboratory parameters, whereas creatinine was part of the NMR-based B.I. QUANT-PS report. In  
435 addition, significant increases in triglyceride-rich VLDL particles were observed, especially in the  
436 larger and less dense subgroups (VLDL-1, -2, -3), as well as in the triglyceride subfractions (VLTG,  
437 V1TG, V2TG). Total plasma triglyceride (TPTG) and IDL triglyceride fraction (IDTG) also showed  
438 elevated levels. Regarding metabolites, the citrate cycle metabolite succinic acid was increased, as in  
439 other analysis. The metabolite trimethylamine-N- oxide (TMAO), which is produced by intestinal  
440 bacteria and is considered a cardiovascular risk marker, only stood out in this analysis.



441  
442 **Fig 5. Metabolomic differences in normotensive and hypertensive COVID-19 patients**  
443 In (A) univariate analysis by means of volcano plot showing significant differences in normotensive and hypertensive COVID-  
444 19 patients ( $FC > 1.2$ ,  $p < 0.05$ ,  $FDR < 0.01$ ): The red features are increased in the COVID-19 + AHT cohort, while the green  
445 ones are decreased in COVID-19 + AHT. (B) Multivariate analysis by means of principal component analysis (PCA) showing  
446 the distribution of both groups. (C) Violin plots showing significant alterations of the cardiovascular risk marker trimethyla-  
447 mine-N-oxide (TMAO) and TPTG. The y-axis shows the normalized concentration. AHT= Arterial hypertension, BP = blood  
448 pressure, BUN = Blood urea nitrogen, Creatinine.lab = Creatinine from laboratory report, Cov = COVID-19.  
449

450 Similar metabolic alterations were observed in hospitalized COVID-19 + AHT patients (Fig. 6). This  
451 group also showed elevated renal values (BUN, creatinine) and a triglyceride-rich lipoprotein profile  
452 compared with normotensive hospitalized COVID-19 patients. However, the lipoprotein subclass  
453 distribution differed from the COVID-19 + AHT group in total in that HDL triglycerides were elevated  
454 in the hospitalized COVID-19 + AHT group. These subgroups were not conspicuous in the previous  
455 comparison (Fig. 5).

456 In particular, another volcano plot analysis was performed with 56 samples from 33 hospitalized  
 457 COVID-19 + AHT patients and 71 samples from 38 normotensive hospitalized COVID-19 patients (Fig  
 458 6). Hereby, 17 features were elevated more than 1.2-fold, one metabolite (creatinine) was decreased.  
 459 Also, in this comparison, creatinine and BUN showed the highest significant alterations. The  
 460 lipoprotein profile of the hospitalized COVID-19 + AHT cohort was characterized by increased total  
 461 triglycerides and triglyceride subfractions (TPTG, VLTG, IDTG), increased VLDL particles in the total  
 462 (VLPN), and in the less dense subfractions (VLDL-1, -2, -3). In addition, all HDL- triglyceride  
 463 subfractions (HDTG, H1TG, H2TG, H3TG), except H4TG, were elevated in the hospitalized,  
 464 hypertensive COVID-19 cohort.




465  
 466 *Fig 6. Metabolomic characteristics of hospitalized COVID-19 patients with AHT*



467 *In (A) univariate analysis by means of volcano plot showing significant differences between normotensive and hypertensive*  
468 *hospitalized COVID-19 patients ( $FC > 1.2$ ,  $p < 0.05$ ,  $FDR < 0.01$ ): The red points show increased features in the hospitalized*  
469 *COVID-19 + AHT cohort, while the green one is decreased. (B) Multivariate analysis by means of principal component analy-*  
470 *sis (PCA) showing the distribution of both groups. In (C) violin plots show the most significant alterations of the NMR param-*  
471 *eter Creatinine and H3TG. The y-axis shows the normalized concentration. AHT= Arterial hypertension, BP= blood pressure,*  
472 *hosp = hospitalized, BUN= Blood urea nitrogen, Creatinine.lab= Creatinine from laboratory report.*  
473

474 Of the 134 hypertensive COVID-19 affected patients, 120 were treated with antihypertensives. 48 of  
475 these were treated with one medication, 72 with two or more. An overview of the medications of the  
476 hypertensive patients was given in Table 1. Antihypertensives indicated were angiotensin-converting-  
477 enzyme inhibitors (ACEI), angiotensin-1 receptor blockers (AT1RB), beta-blockers (BB), and calcium  
478 channel blockers (CCB). To determine any medication differences in metabolites and lipoproteins,  
479 the COVID-19 + AHT cohort was divided into subgroups according to their antihypertensive  
480 treatment. Patients treated with ACEI and/or AT1RB alone were grouped as the renin-angiotensin-  
481 aldosterone system inhibitor (RAASI) group, which included 75 samples. Hypertensive patients  
482 treated with BB and/or CCB formed the no RAASI group, which included 40 samples. The majority in  
483 this group were treated with BB (29 samples). 75 samples were from patients treated with different  
484 combinations of ACEI/AT1RB and BB and/or CCB. The 26 samples from patients who were not taking  
485 antihypertensives according to metadata were excluded from this analysis. The groups were  
486 compared with univariate operations. Here, the RAASI- group showed improved renal values  
487 compared with the no RAASI group, in terms of decreased creatinine levels and higher glomerular  
488 filtration rate (GFR). This was not observed when patients were treated with a combination of RAASI  
489 and BB or CCB. In general, no significant alterations could be seen in the comparison of a  
490 combination of RAASI with BB/CCB versus the no RAASI group. Interestingly, increased VLDL particles  
491 (VLPN), consisting of the denser subgroups VLDL-4, were observed in the RAASI group. All significant

492 changes are shown in the volcano plot in Fig 7.



493

494 **Fig 7. Hypertensive COVID-19 patients show improved kidney values under treatment with renin- angiotensin-aldoste-**  
 495 **rone- inhibitors (RAASI)**

496 *In (A) univariate comparison by means of volcano plot analysis ( $FC > 1.2$ ,  $p < 0.05$ ,  $FDR < 0.01$ ): The red features correspond*  
 497 *to increased values in the RAASI group, while the green ones correspond to decreased values. (B) Multivariate analysis by*  
 498 *means of principal component analysis (PCA) showing the distribution of both groups. (C) Violin plots show significant alter-*  
 499 *ations in the kidney parameters Creatinine and GFR = glomerular filtration rate. The y-axis shows the normalized concentra-*  
 500 *tion. Creatinine.lab= Creatinine from laboratory report.*

501

## 502 Hypertensive COVID-19 patients show higher inflammatory parameters


503 As a further univariate test method, an unpaired t-test was performed with the cohorts AHT versus

504 COVID-19 + AHT. Another unpaired t-test was performed for the comparison COVID-19 with AHT

505 versus regular BP. The p-value threshold was set at 0.05 ( $FDR < 0.01$ ). These t-tests were performed

506 for the already mentioned typical altered metabolites (glutamine, isoleucine, leucine, lysine, citric

507 acid) and lipoproteins (HDL-4, TPCH, LDCH, SPC) in COVID-19 patients. The results are shown using  
508 violin plots in the supplementary data S20. It was additionally observed that hypertensive COVID-19  
509 patients showed higher inflammation levels than normotensives. This was true for the NMR  
510 parameters Glyc, as well as the Glyc/SPC ratio, with the hypertensive COVID-19 group showing  
511 significantly higher values with p-values of  $p = 0.0014$  for Glyc and  $p = 0.0058$  for Glyc/SPC ratio. SPC  
512 was decreased in normotensive COVID-19 patients compared to the cohort without COVID-19 and  
513 therefore did not stand out as significant in this comparison, same for the laboratory value CRP,  
514 which was increased in normotensive and hypertensive COVID-19 patients. Violin plots for the  
515 mentioned inflammatory parameters are shown in Fig 8.  
516



517  
518 **Fig 8. COVID-19 patients with AHT show higher inflammatory NMR parameters**  
519 Violin plots showing the inflammatory NMR parameters Glyc/SPC (A), SPC (B), Glyc (C), and routine lab CRP (D). Unpaired t-  
520 tests were performed for the comparison of AHT versus COVID-19 + AHT, and COVID-19 with and without AHT. Significant  
521 alterations are shown in form of asterisks: ns (not significant),  $p < 0.05$  (\*),  $p < 0.01$  (\*\*),  $p < 0.001$  (\*\*\*),  $p < 0.0001$  (\*\*\*\*). The  
522 y-axis shows the normalized concentration. AHT= Arterial hypertension, Cov= COVID-19, BP= Blood pressure, CRP= C-reactive  
523 protein.  
524

## 525 Discussion

526 In this study, we analyzed a COVID-19 cohort with 509 serum samples from 329 patients, which were  
527 treated mainly in an outpatient care setting. In our analyses, we focused on 134 patients (216  
528 samples), which were additionally affected by arterial hypertension. To the best of our knowledge,

529 this is the first study to investigate the effect of AHT on COVID-19 in the context of NMR- based  
530 metabolomics. We could show that the metabolic changes of COVID-19 disease behave differently  
531 when pre-existing AHT is considered. Stratification for AHT has also an impact on differences  
532 detected between genders. Furthermore, it became clear that hypertensive COVID-19 patients might  
533 at higher risk for complications, shown by certain changes in lipoproteins, metabolites, and  
534 inflammatory parameters.

535 The Coronataxi study took place in Germany, where, according to the Robert-Koch- Institute, AHT  
536 prevalence is about one-third in women and men, respectively. In subjects older than 65 years  
537 prevalence is even two third for both genders. In our COVID-19 cohort AHT was also very present  
538 with 40.7%. Previously it has been shown that individuals with pre-existing cardiovascular disease  
539 have an altered metabolic profile, particularly with respect to lipoproteins. These include, among  
540 others, increased VLDL particles and decreased HDL levels (31, 35). Since hypertensive patients may  
541 thus have elevated VLDL levels, they obviously drop out in the univariate statistics when COVID-19  
542 patients with hypertension are compared with controls with hypertension, leading to the hypothesis  
543 that COVID-19, at least in milder courses, does not cause an increase in VLDL and its subgroups, as  
544 well as in the ABA1 ratio. However, what does suggest dyslipidemia in COVID-19-affected individuals  
545 despite this are the decreased levels in the HDL fractions. In particular, the decreased levels in the  
546 dense HDL-4 particles are considered typical of COVID-19 in our cohort. HDL appears to correlate  
547 inversely with cardiovascular risk (36). However, there are discrepancies in the extent to which the  
548 various HDL subgroups are involved in this process (37). Furthermore, since different methods are  
549 used to measure HDL subgroups, it is not always easy to compare the literature in this regard. Small  
550 HDL particles, such as HDL-4 (corresponding to HDL-3 in ultracentrifugation (38)), have been shown  
551 in some studies to be risk factors for cardiovascular disease (39). On the other hand, the protective  
552 and antioxidant effects on the endothelium (40) and the fibrinolytic properties of denser HDL  
553 particles had been described. (41). Apolipoproteins A1 and A2 each play a major role, as well as  
554 inverse correlating markers for cardiovascular risk (42). Adjacent to cardiovascular disease, HDL has a

555 more clear relationship with the immune system (43, 44) and changes in its composition and function  
556 during an acute phase reaction (45). This is characterized by a decrease in apolipoprotein A1 and HDL  
557 cholesterol, which was evident in our COVID-19 cohort where we identified a decrease in total (TPA1  
558 and TPCH, respectively) and HDL groups HDA1 and H4A1, and HDCH and H4CH, respectively. Thus, it  
559 can be inferred that the acute-phase response induced by COVID-19 may cause dysfunctionality of  
560 HDL particles, leading to loss of atheroprotective properties (46). In addition to the decrease in HDL-  
561 particles, several LDL- fractions also showed a decrease. This is consistent with other studies (8, 14).  
562 Furthermore, a correlation between increasing disease severity and a decrease in LDL cholesterol, as  
563 well as an inverse correlation between LDL cholesterol and CRP could be observed (47, 48). Possible  
564 reasons for this include impaired liver function, altered lipid metabolism under the influence of  
565 cytokines, and the breakdown of lipids by free radicals (47).

#### 566 **General metabolic differences in COVID-19 patients**

567 Regarding metabolites, COVID-19 characteristics include decreases in amino acids glutamine,  
568 isoleucine, leucine, and lysine. This indicates an altered energy metabolism in the course of  
569 hypoxemia (49). Decreased glutamine correlated inversely with CRP, lactate dehydrogenase (LDH),  
570 and partial pressure of oxygen in this study (49). In addition, glutamine fulfills important functions in  
571 the body, e.g. as a reactant for glutathione biosynthesis or as an energy supplier for immune cells  
572 (50). The reduction in the other amino acids mentioned could indicate increased amino acid  
573 catabolism, possibly as a result of temporary fasting during acute infection, as of our COVID-19  
574 cohort, 22% reported loss of appetite and 9% nausea. Another metabolite that is decreased in  
575 COVID-19 is citric acid. This Krebs cycle metabolite also correlated inversely with CRP and LDH in one  
576 study (51).

#### 577 **The role of AHT on previous findings**

578 Comparing the AHT- control cohort with the COVID-19 + AHT cohort, the acute phase protein CRP  
579 showed an increase, which is not surprising, as well as the NMR-based inflammatory parameter

580 Glyc/SPC. This ratio was also elevated in another study of COVID-19 patients (28). Glycoproteins  
581 (Glyc) represent the acute phase reaction (23). Supramolecular Phospholipid Composite signal (SPC)  
582 reproduces lipoproteins, especially apolipoproteins and HDL (28). Another prominent parameter in  
583 the COVID-19 cohort was phenylalanine. It has already been mentioned that this amino acid is  
584 elevated in COVID-19 patients and also correlates with a more severe progression (17). Even before  
585 the COVID-19 pandemic, phenylalanine was shown to be elevated in severe infections and associated  
586 with increased mortality, intensive care unit (ICU) treatment, and CRP levels (52). The elevated  
587 phenylalanine levels may be related to impaired liver or kidney function, as the hydroxylation of  
588 phenylalanine to tyrosine occurs in these organs (53). At the same time, tyrosine levels are reduced  
589 in the COVID-19 + AHT cohort, raising further suspicion that this process may be impaired, as it is also  
590 the case in patients with severe liver injury (54), and chronic kidney failure (55). The increased levels  
591 of glutamic acid in the COVID-19 patients may result from an increased supply from glutamine, for  
592 the synthesis of glutathione as an antioxidant or as an alternative energy resource for  
593 gluconeogenesis (56). Furthermore, COVID-19 patients exhibit elevated levels of the Krebs cycle  
594 intermediate succinic acid. This is possibly an expression of a hypoxic metabolic state, since succinic  
595 acid is able to stabilize hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) (57) and also to force the interleukin  
596 production (58).

### 597 **Gender differences in COVID-19**

598 Male sex is a known risk factor for severe COVID-19 progression and complications (59, 60). In our  
599 gender comparison of COVID-19 individuals, several parameters could be identified as markers for an  
600 unfavorable disease course. These included elevated ketone bodies (acetone, acetoacetic acid, 3-  
601 hydroxybutyric acid) and marked dyslipidemia (16). The latter was indicated by increased VLDL  
602 particles in males and decreased HDL levels compared to female SARS-CoV-2 infected individuals.  
603 From this, one could deduce that the risk factor "male gender" can also be observed in the  
604 metabolome. However, a different picture emerged when the AHT factor was also included in this  
605 comparison. Only isolated VLDL particles then showed increased values. Ketone bodies, Glyc/SPC and

606 HDL particles were also no longer found to be significantly altered. The sex differences were mainly  
607 related to an increase in various LDL fractions in women, as well as an increase in the BCAAs leucine  
608 and isoleucine, citric acid, and three VLDL particles. The elevated levels of dimethyl sulfone in our  
609 study could be attributed to two patients with very high levels and is possibly the result of a specific  
610 diet. However, considering sex and AHT, there were also some common features that, although not  
611 specific for COVID-19, emerged as typical metabolic profile in with SARS-CoV-2 infected individuals.  
612 These included increases in CRP and Glyc/SPC, and decreases in glutamine, isoleucine, leucine, lysine,  
613 citric acid, HDL-4 subsets, total cholesterol, LDL- cholesterol, and SPC. This is consistent with other  
614 metabolomics studies (8, 9, 13, 14) on COVID-19 but gives a finer picture of metabolic characteristics.

#### 615 **AHT as risk factor in COVID-19: What can be seen in the metabolome?**

616 AHT has also previously been cited as a risk factor for severe COVID-19 progression (4) and is also  
617 associated with an increased risk of various cardiovascular complications, such as heart failure or  
618 acute coronary syndrome (61). In addition to the already discussed changes in the lipoproteome in  
619 cardiac pre-diseased patients, the metabolite trimethylamine-N-oxides (TMAO) should also be  
620 mentioned. This metabolite, which is synthesized by intestinal bacteria, is considered a  
621 cardiovascular risk marker due to its proatherosclerotic effects. (62).

622 As expected, also in our cohort with mostly milder courses, hypertensive COVID-19 patients showed  
623 an increase in the mentioned cardiovascular risk markers compared with normotensive COVID-19  
624 affected individuals. Interestingly, the ABA1 ratio did not stand out as significantly elevated in  
625 hypertensive patients in our cohort. Furthermore, signs of impaired renal function were clearly  
626 observed in hypertensive COVID-19 patients. However, these markers are less an expression of  
627 COVID-19 but rather due to AHT as such. Thus, when comparing the AHT- cohorts with and without  
628 COVID-19, there was no increase in these parameters and thus no further deterioration of renal  
629 function during acute infection. However, an indication of renal impairment in the COVID-19 + AHT  
630 cohort, is the observation that tyrosine was found to be significantly decreased in hypertensives only

631 in the comparison AHT with and without COVID-19. The triglyceride-rich lipoprotein profile also did  
632 not appear to be linked to COVID-19. Succinic acid, which was elevated in hypertensives, could  
633 represent a more severe COVID-19 course as an expression of a hypoxic metabolic state (57). TMAO,  
634 which was increased in hypertensive COVID-19 patients, was also associated with a more severe  
635 COVID-19 course in patients with pre-existing diabetes mellitus or cardiovascular diseases in one  
636 study (63). Also, COVID-19 patients with pre-existing AHT showed higher inflammatory values in  
637 terms of Glyc and Glyc/SPC ratio in our study compared to patients without pre-existing AHT.  
638 Comparing hospitalized COVID-19 patients with and without AHT, it was also not surprising that  
639 COVID-19 patients with AHT had higher renal values (creatinine, BUN), as well as a lipoprotein profile  
640 rich in triglycerides.

#### 641 **Influence of various antihypertensives on COVID-19 + AHT patients**

642 With regard to antihypertensive treatment, the use of angiotensin converting enzyme inhibitors  
643 (ACEI) and angiotensin II receptor blockers (ARB) was discussed at the beginning of the pandemic. It  
644 was suspected that these classes of drugs, by increasing the expression of ACE-2 receptors, would  
645 lead to increased viral uptake into cells and thus to a worse course of COVID-19 disease (64).  
646 However, it has now been shown that treatment with ACEIs and ARBs is not associated with a more  
647 severe disease course or increased mortality, but rather the opposite, and blood pressure control is  
648 an important factor in COVID-19 treatment (65, 66). Also in our results, COVID-19 + AHT patients,  
649 treated with this group of drugs had lower mean levels of renal creatinine and a higher GFR than  
650 patients treated with other antihypertensives. However, with the use of RAASI, there was also an  
651 increase in some VLDL particles. This could be due to a higher number of multimorbid patients in this  
652 group.

#### 653 **Conclusion**

654 Here, we presented an NMR-based study examining serum from a large cohort of outpatients and  
655 hospitalized COVID-19 patients. Extensive meta-data allowed us to relate to common laboratory



656 parameters, as well as to include in our analyses the important comorbidity AHT, which occurs with  
657 high prevalence. This provides a much finer picture of the metabolic fingerprint of COVID-19 disease.  
658 The extensive quantification of metabolites and lipoproteins with an uncomplicated and rapid  
659 measurement method such as NMR opens many possibilities in the field of pathophysiology research  
660 and risk stratification, which has not yet been conclusively elucidated in COVID-19.

661 We are aware that the statistical power is diminished by larger differences in cohort sizes and by the  
662 fact that no comparisons of laboratory parameters and parameter from the B.I. PACS™ report could  
663 be included in the comparison of the COVID-19 patient cohort with the healthy control group from  
664 Bruker (HC).

#### 665 **Funding**

666 This project was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research  
667 Foundation)- project number 374031971- TRR 240.

#### 668 **Acknowledgments**

669 We thank the Werner Siemens Imaging Center with the Chair of Department Prof. Dr. Pichler for the  
670 opportunity to perform this research. In addition, we greatly thank Karin Tarbet from the Coronataxi-  
671 team for her great work and effort and the medical technicians Petra Klöters-Plachky and Alexandra  
672 Hof for their biobanking work. Further, we want to thank the members of CRC/TR240 project Z03  
673 (Cornelia Fiessler, Anna Grau, Steffi Jiru-Hillmann, Kirsten Haas) from the institute for clinical  
674 epidemiology and biometry, University Hospital Würzburg, Würzburg, Germany and Frederic  
675 Emschermann from the Department of Internal Medicine III, Cardiology and Angiology, University  
676 Hospital Tübingen, Tübingen, Germany for the good cooperation. We also thank our technical  
677 assistants Miriam Owczorz and Daniele Bucci for the support during sample preparation and NMR  
678 measurements.

679

680

## 681 References:

- 682 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of  
683 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*.  
684 2020;395(10229):1054-62.
- 685 2. Scudiero F, Silverio A, Di Maio M, Russo V, Citro R, Personeni D, et al. Pulmonary embolism in  
686 COVID-19 patients: prevalence, predictors and clinical outcome. *Thrombosis Research*. 2021;198:34-  
687 9.
- 688 3. Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. *JCI Insight*.  
689 2021;6(13).
- 690 4. Gao Y-d, Ding M, Dong X, Zhang J-j, Kursat Azkur A, Azkur D, et al. Risk factors for severe and  
691 critically ill COVID-19 patients: A review. *Allergy*. 2021;76(2):428-55.
- 692 5. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With  
693 COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health*. 2020;8.
- 694 6. Letertre MPM, Giraudeau P, de Tullio P. Nuclear Magnetic Resonance Spectroscopy in Clinical  
695 Metabolomics and Personalized Medicine: Current Challenges and Perspectives. *Front Mol Biosci*.  
696 2021;8:698337-.
- 697 7. Pang H, Jia W, Hu Z. Emerging applications of metabolomics in clinical pharmacology. *Clinical*  
698 *Pharmacology & Therapeutics*. 2019;106(3):544-56.
- 699 8. Bruzzone C, Bizkarguenaga M, Gil-Redondo R, Diercks T, Arana E, García de Vicuña A, et al.  
700 SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum. *iScience*.  
701 2020;23(10):101645.
- 702 9. Baranovicova E, Bobcakova A, Vysehradsky R, Dankova Z, Halasova E, Nosal V, et al. The  
703 Ability to Normalise Energy Metabolism in Advanced COVID-19 Disease Seems to Be One of the Key  
704 Factors Determining the Disease Progression—A Metabolomic NMR Study on Blood Plasma. *Applied*  
705 *Sciences*. 2021;11(9):4231.
- 706 10. Dierckx T, van Elslande J, Salmela H, Decru B, Wauters E, Gunst J, et al. The metabolic  
707 fingerprint of COVID-19 severity. *medRxiv*. 2020:2020.11.09.20228221.
- 708 11. Ghini V, Meoni G, Pelagatti L, Celli T, Veneziani F, Petrucci F, et al. Profiling metabolites and  
709 lipoproteins in COMETA, an Italian cohort of COVID-19 patients. *PLOS Pathogens*.  
710 2022;18(4):e1010443.
- 711 12. Schmelter F, Foeh B, Mallagaray A, Rahmoeller J, Ehlers M, Lehrian S, et al. Metabolic  
712 markers distinguish COVID-19 from other intensive care patients and show potential to stratify for  
713 disease risk. *medRxiv*. 2021:2021.01.13.21249645.
- 714 13. Lodge S, Nitschke P, Kimhofer T, Coudert JD, Begum S, Bong S-H, et al. NMR Spectroscopic  
715 Windows on the Systemic Effects of SARS-CoV-2 Infection on Plasma Lipoproteins and Metabolites in  
716 Relation to Circulating Cytokines. *Journal of Proteome Research*. 2021;20(2):1382-96.
- 717 14. Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, et al. Integrative Modeling of  
718 Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological  
719 Signature of SARS-CoV-2 Infection. *Journal of proteome research*. 2020;19(11):4442--54 , pmid =  
720 32806897.
- 721 15. Aboelela MI, Abd Elmajeed AD, Abd Elmaksoud H, Sayed AA. A Study on APO B100/APO A1  
722 Ratio as A Predictive Parameter for Assessment of CAD Risk in Uncontrolled Type 2 Egyptian Diabetic  
723 Patients. *The Egyptian Journal of Hospital Medicine*. 2014;54(1):62-70.
- 724 16. Rendeiro AF, Vorkas CK, Krumsiek J, Singh H, Kapatia S, Cappelli LV, et al. Metabolic and  
725 immune markers for precise monitoring of COVID-19 severity and treatment. *medRxiv*.  
726 2021:2021.09.05.21263141.
- 727 17. Luporini RL, Pott-Junior H, Di Medeiros Leal MCB, Castro A, Ferreira AG, Cominetti MR, et al.  
728 Phenylalanine and COVID-19: Tracking disease severity markers. *International Immunopharmacology*.  
729 2021;101:108313.
- 730 18. Feingold KR. Lipid and Lipoprotein Levels in Patients with COVID-19 Infections. In: Feingold  
731 KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. *Endotext*. South  
732 Dartmouth (MA): MDTText.com, Inc.

- 733 Copyright © 2000-2022, MDText.com, Inc.; 2022.
- 734 19. Meoni G, Ghini V, Maggi L, Vignoli A, Mazzoni A, Salvati L, et al. Metabolomic/lipidomic  
735 profiling of COVID-19 and individual response to tocilizumab. *PLOS Pathogens*. 2021;17(2):e1009243.
- 736 20. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute  
737 COVID-19 syndrome. *Nature Medicine*. 2021;27(4):601-15.
- 738 21. Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, et al. Incomplete Systemic  
739 Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients:  
740 Implications for Assessment of Post-Acute COVID-19 Syndrome. *Journal of proteome research*.  
741 2021;20(6):3315--29 , pmid = 34009992.
- 742 22. Liptak P, Baranovicova E, Rosolanka R, Simekova K, Bobcakova A, Vysehradsky R, et al.  
743 Persistence of Metabolomic Changes in Patients during Post-COVID Phase: A Prospective,  
744 Observational Study. *Metabolites*. 2022;12(7):641.
- 745 23. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: A  
746 Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. *Clinical Chemistry*.  
747 2015;61(5):714-23.
- 748 24. Fuertes-Martín R, Taverner D, Vallvé J-C, Paredes S, Masana L, Correig Blanchar X, et al.  
749 Characterization of 1H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory  
750 Patterns in Rheumatoid Arthritis. *Journal of Proteome Research*. 2018;17(11):3730-9.
- 751 25. Nitschke P, Lodge S, Kimhofer T, Masuda R, Bong S-H, Hall D, et al. J-Edited Diffusional Proton  
752 Nuclear Magnetic Resonance Spectroscopic Measurement of Glycoprotein and Supramolecular  
753 Phospholipid Biomarkers of Inflammation in Human Serum. *Analytical Chemistry*. 2022;94(2):1333-  
754 41.
- 755 26. Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, et al. Relations of GlycA  
756 and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of  
757 the AIM-HIGH trial. *Journal of Clinical Lipidology*. 2018;12(2):348-55.e2.
- 758 27. Chiesa ST, Charakida M, Georgiopoulos G, Roberts JD, Stafford SJ, Park C, et al. Glycoprotein  
759 Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. *Journal of the*  
760 *American Heart Association*. 2022;11(4):e024380.
- 761 28. Lodge S, Nitschke P, Kimhofer T, Wist J, Bong S-H, Loo RL, et al. Diffusion and Relaxation  
762 Edited Proton NMR Spectroscopy of Plasma Reveals a High-Fidelity Supramolecular Biomarker  
763 Signature of SARS-CoV-2 Infection. *Analytical Chemistry*. 2021;93(8):3976-86.
- 764 29. Ameta K, Gupta A, Kumar S, Sethi R, Kumar D, Mahdi AA. Essential hypertension: A filtered  
765 serum based metabolomics study. *Scientific Reports*. 2017;7(1):2153.
- 766 30. Deng Y, Huang C, Su J, Pan C-W, Ke C. Identification of biomarkers for essential hypertension  
767 based on metabolomics. *Nutrition, Metabolism and Cardiovascular Diseases*. 2021;31(2):382-95.
- 768 31. Nayak P, Panda S, Thatoi PK, Rattan R, Mohapatra S, Mishra PK. Evaluation of Lipid Profile  
769 and Apolipoproteins in Essential Hypertensive Patients. *J Clin Diagn Res*. 2016;10(10):BC01-BC4.
- 770 32. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite  
771 Profiling and Cardiovascular Event Risk. *Circulation*. 2015;131(9):774-85.
- 772 33. Del Coco L, Vergara D, De Matteis S, Mensà E, Sabbatinelli J, Prattichizzo F, et al. NMR-Based  
773 Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with  
774 Type 2 Diabetes Mellitus. *Journal of Clinical Medicine*. 2019;8(5):720.
- 775 34. Lim A, Hippchen T, Unger I, Heinze O, Welker A, Kräusslich H-G, et al. An Outpatient  
776 Management Strategy Using a Coronataxi Digital Early Warning System Reduces Coronavirus Disease  
777 2019 Mortality. *Open Forum Infectious Diseases*. 2022;9(4).
- 778 35. Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, et al. Lipids,  
779 Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. *Journal of*  
780 *the American College of Cardiology*. 2018;71(6):620-32.
- 781 36. Rader DJ, Hovingh GK. HDL and cardiovascular disease. *The Lancet*. 2014;384(9943):618-25.
- 782 37. Superko HR, Pendyala L, Williams PT, Momary KM, King SB, Garrett BC. High-density  
783 lipoprotein subclasses and their relationship to cardiovascular disease. *Journal of Clinical Lipidology*.  
784 2012;6(6):496-523.

- 785 38. Gebhard C, Rhainds D, Tardif J-C. HDL and cardiovascular risk: is cholesterol in particle  
786 subclasses relevant? *European Heart Journal*. 2014;36(1):10-2.
- 787 39. Piko P, Kosa Z, Sandor J, Seres I, Paragh G, Adany R. The profile of HDL-C subfractions and  
788 their association with cardiovascular risk in the Hungarian general and Roma populations. *Scientific*  
789 *Reports*. 2022;12(1):10915.
- 790 40. De Souza JA, Vindis C, Nègre-Salvayre A, Rye K-A, Couturier M, Therond P, et al. Small, dense  
791 HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. *Journal of*  
792 *Cellular and Molecular Medicine*. 2010;14(3):608-20.
- 793 41. Harbaum L, Ghataorhe P, Wharton J, Jiménez B, Howard LSG, Gibbs JSR, et al. Reduced  
794 plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial  
795 hypertension. *Thorax*. 2019;74(4):380-9.
- 796 42. Florvall G, Basu S, Larsson A. Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are  
797 HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men. *The Journals of*  
798 *Gerontology: Series A*. 2006;61(12):1262-6.
- 799 43. Nazir S, Jankowski V, Bender G, Zewinger S, Rye K-A, van der Vorst EPC. Interaction between  
800 high-density lipoproteins and inflammation: Function matters more than concentration! *Advanced*  
801 *Drug Delivery Reviews*. 2020;159:94-119.
- 802 44. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, et al.  
803 Inflammation modulates human HDL composition and function in vivo. *Atherosclerosis*.  
804 2012;222(2):390-4.
- 805 45. Bindu G H, Rao VS, Kakkar VV. Friend Turns Foe: Transformation of Anti-Inflammatory HDL to  
806 Proinflammatory HDL during Acute-Phase Response. *Cholesterol*. 2011;2011:274629.
- 807 46. Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional  
808 HDL and atherosclerotic cardiovascular disease. *Nature Reviews Cardiology*. 2016;13(1):48-60.
- 809 47. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity  
810 of COVID-19. *Journal of Clinical Lipidology*. 2020;14(3):297-304.
- 811 48. Mahat RK, Rathore V, Singh N, Singh N, Singh SK, Shah RK, et al. Lipid profile as an indicator  
812 of COVID-19 severity: A systematic review and meta-analysis. *Clinical Nutrition ESPEN*. 2021;45:91-  
813 101.
- 814 49. Páez-Franco JC, Torres-Ruiz J, Sosa-Hernández VA, Cervantes-Díaz R, Romero-Ramírez S,  
815 Pérez-Fragoso A, et al. Metabolomics analysis reveals a modified amino acid metabolism that  
816 correlates with altered oxygen homeostasis in COVID-19 patients. *Scientific Reports*.  
817 2021;11(1):6350.
- 818 50. de Oliveira DC, da Silva Lima F, Sartori T, Santos ACA, Rogero MM, Fock RA. Glutamine  
819 metabolism and its effects on immune response: molecular mechanism and gene expression. *Nutrire*.  
820 2016;41(1):14.
- 821 51. Shi D, Yan R, Lv L, Jiang H, Lu Y, Sheng J, et al. The serum metabolome of COVID-19 patients is  
822 distinctive and predictive. *Metabolism*. 2021;118:154739.
- 823 52. Huang S-S, Lin J-Y, Chen W-S, Liu M-H, Cheng C-W, Cheng M-L, et al. Phenylalanine- and  
824 leucine-defined metabolic types identify high mortality risk in patients with severe infection.  
825 *International Journal of Infectious Diseases*. 2019;85:143-9.
- 826 53. Møller N, Meek S, Bigelow M, Andrews J, Nair KS. The kidney is an important site for *in*  
827 *vivo* phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney.  
828 *Proceedings of the National Academy of Sciences*. 2000;97(3):1242-6.
- 829 54. Tessari P, Vettore M, Million R, Puricelli L, Orlando R. Effect of liver cirrhosis on  
830 phenylalanine and tyrosine metabolism. *Current Opinion in Clinical Nutrition & Metabolic Care*.  
831 2010;13(1):81-6.
- 832 55. Boirie Y, Albright R, Bigelow M, Nair KS. Impairment of phenylalanine conversion to tyrosine  
833 in end-stage renal disease causing tyrosine deficiency. *Kidney International*. 2004;66(2):591-6.
- 834 56. Newsholme P, Procopio J, Lima MMR, Pithon-Curi TC, Curi R. Glutamine and glutamate—  
835 their central role in cell metabolism and function. *Cell Biochemistry and Function*. 2003;21(1):1-9.

- 836 57. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al.  
837 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- $\alpha$  prolyl hydroxylase. *Cancer*  
838 *Cell*. 2005;7(1):77-85.
- 839 58. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al.  
840 Succinate is an inflammatory signal that induces IL-1 $\beta$  through HIF-1 $\alpha$ . *Nature*. 2013;496(7444):238-  
841 42.
- 842 59. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and  
843 Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.  
844 *Intervirology*. 2021;64(1):36-47.
- 845 60. Viveiros A, Rasmuson J, Vu J, Mulvagh SL, Yip CYY, Norris CM, et al. Sex differences in COVID-  
846 19: candidate pathways, genetics of ACE2, and sex hormones. *American Journal of Physiology-Heart*  
847 *and Circulatory Physiology*. 2021;320(1):H296-H304.
- 848 61. Lee CCE, Ali K, Connell D, Mordi IR, George J, Lang EM, et al. COVID-19-Associated  
849 Cardiovascular Complications. *Diseases*. 2021;9(3):47.
- 850 62. Papandreou C, Moré M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic  
851 health—cause or effect? *Nutrients*. 2020;12(5):1330.
- 852 63. Terruzzi I, Senesi P. Does intestinal dysbiosis contribute to an aberrant inflammatory  
853 response to severe acute respiratory syndrome coronavirus 2 in frail patients? *Nutrition*. 2020;79-  
854 80:110996.
- 855 64. Khashkusha TR, Chan JSK, Harky A. ACE inhibitors and COVID-19: We don't know yet. *J Card*  
856 *Surg*. 2020;35(6):1172-3.
- 857 65. Sharma R, Kumar A, Majeed J, Thakur AK, Aggarwal G. Drugs acting on the renin-  
858 angiotensin-aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and  
859 meta-analysis of observational studies. *The Egyptian Heart Journal*. 2022;74(1):64.
- 860 66. Lee T, Cau A, Cheng MP, Levin A, Lee TC, Vinh DC, et al. Angiotensin Receptor Blockers and  
861 Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for  
862 Confounding Factors. *CJC Open*. 2021;3(7):965-75.

863